TW201842933A - 使用il-17拮抗劑選擇性治療氣喘的方法 - Google Patents

使用il-17拮抗劑選擇性治療氣喘的方法 Download PDF

Info

Publication number
TW201842933A
TW201842933A TW107114983A TW107114983A TW201842933A TW 201842933 A TW201842933 A TW 201842933A TW 107114983 A TW107114983 A TW 107114983A TW 107114983 A TW107114983 A TW 107114983A TW 201842933 A TW201842933 A TW 201842933A
Authority
TW
Taiwan
Prior art keywords
seq
patient
antagonist
antibody
immunoglobulin
Prior art date
Application number
TW107114983A
Other languages
English (en)
Chinese (zh)
Inventor
莎拉 施密特 葛蘭
珊莎 卡薩尼
愛德華 寇克羅維奇
傑森 拉勒米
羅伯特 馬丁 史椎特
崔西亞 安 桑頓－威爾斯
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW201842933A publication Critical patent/TW201842933A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW107114983A 2017-05-05 2018-05-03 使用il-17拮抗劑選擇性治療氣喘的方法 TW201842933A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05
US62/501,806 2017-05-05

Publications (1)

Publication Number Publication Date
TW201842933A true TW201842933A (zh) 2018-12-16

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107114983A TW201842933A (zh) 2017-05-05 2018-05-03 使用il-17拮抗劑選擇性治療氣喘的方法

Country Status (13)

Country Link
US (1) US10676522B2 (enExample)
EP (1) EP3619536A1 (enExample)
JP (1) JP2020518604A (enExample)
KR (1) KR20190142398A (enExample)
CN (1) CN110582702A (enExample)
AU (1) AU2018263159A1 (enExample)
BR (1) BR112019023141A2 (enExample)
CA (1) CA3062179A1 (enExample)
CL (1) CL2019003161A1 (enExample)
MX (1) MX2019013160A (enExample)
RU (1) RU2019139387A (enExample)
TW (1) TW201842933A (enExample)
WO (1) WO2018203289A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
WO2021211430A1 (en) * 2020-04-17 2021-10-21 Eli Lilly And Company Treatment of respiratory disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP6161233B2 (ja) 2008-03-31 2017-07-12 ジェネンテック， インコーポレイテッド 喘息の治療及び診断のための組成物及び方法
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
MX371052B (es) 2013-02-08 2020-01-14 Novartis Ag Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios.
BR112016008694A2 (pt) * 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
WO2015191783A2 (en) * 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US11278618B2 (en) * 2014-09-10 2022-03-22 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Also Published As

Publication number Publication date
CL2019003161A1 (es) 2020-02-07
MX2019013160A (es) 2020-02-05
BR112019023141A2 (pt) 2020-07-28
JP2020518604A (ja) 2020-06-25
US20180319881A1 (en) 2018-11-08
KR20190142398A (ko) 2019-12-26
RU2019139387A (ru) 2021-06-07
CN110582702A (zh) 2019-12-17
CA3062179A1 (en) 2018-11-08
EP3619536A1 (en) 2020-03-11
US10676522B2 (en) 2020-06-09
AU2018263159A1 (en) 2019-11-07
WO2018203289A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
JP7842268B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP6306588B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
TWI757893B (zh) Il-4r拮抗劑用於製造治療鼻息肉症的藥物之用途
KR102460040B1 (ko) 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
KR20230175245A (ko) 변형된 항-tslp 항체
TW201517917A (zh) 使用ｉｌ-１７拮抗劑治療類風濕性關節炎之方法
KR20200088857A (ko) Il-17 길항제에 의한 화농성 한선염의 치료
US20230235069A1 (en) Treatment of atopic dermatitis
JP2019521156A (ja) Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
US10676522B2 (en) Methods of selectively treating asthma using IL-17 antagonists
CN115867577A (zh) 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
JP2023505215A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
TW202126699A (zh) 用於抗類胰蛋白酶抗體之投藥
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
JP7343547B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
WO2025210099A1 (en) Method of treatment and selecting a subject
TW202532439A (zh) 治療氣喘之方法
AU2023393624A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
CN119923276A (zh) 用于治疗患有中度至重度系统性红斑狼疮的患者的抗cd38抗体的皮下给药
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途
JP2021176886A (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法